All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Symmetric dimethylarginine (SDMA) is one of the byproducts of protein methylation, and it has been previously identified as an independent cardiovascular risk factor in patients with chronic kidney disease. The majority of SDMA is excreted through renal tubules; however, its effect on kidney in pathological conditions is not fully understood. In a recent study, researchers from Shuguang Hospital aimed to investigate the role of SDMA in renal tubulointerstitial fibrosis.
Rona Therapeutics Inc. and Keymed Biosciences Co. Ltd. have established a collaboration to jointly discover and develop first-in-class siRNA therapeutics for glomerulonephritis. The collaboration will leverage both companies’ scientific and technological expertise and will build on Rona’s proprietary platform in RNAi targeting liver and extrahepatic tissues.
The limited state of current clinical transplantation science was recently the subject of an opinion piece from an individual that received her first heart transplant at just 25 years of age only to soon succumb at the age of 60 to one of the many risky outcomes expected for anyone taking standard requisite immunosuppression regimens used for any transplantation, in her case terminal cancer.